The Relationship Between Guideline-Recommended Initiation of Therapy, Outcomes, and Cost for Patients with Metastatic Non-Small Cell Lung Cancer | Zendy

Adrianne Waldman Casebeer | Zendy; Dana Drzayich Antol | Zendy; Richard W DeClue | Zendy; Sari Hopson | Zendy; Yong Li | Zendy; Raya Khoury | Zendy; Todd P. Michael | Zendy; Marina Sehman | Zendy; Aparna R. Parikh | Zendy; Stephen Stemkowski | Zendy; Mikele Bunce | Zendy

Open Access

The Relationship Between Guideline-Recommended Initiation of Therapy, Outcomes, and Cost for Patients with Metastatic Non-Small Cell Lung Cancer

Author(s) -

Adrianne Waldman Casebeer,

Dana Drzayich Antol,

Richard W DeClue,

Sari Hopson,

Yong Li,

Raya Khoury,

Todd P. Michael,

Marina Sehman,

Aparna R. Parikh,

Stephen Stemkowski,

Mikele Bunce

Publication year - 2018

Publication title -

journal of managed care and specialty pharmacy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.126

H-Index - 63

eISSN - 2376-1032

pISSN - 2376-0540

DOI - 10.18553/jmcp.2018.24.6.554

Subject(s) - medicine , guideline , lung cancer , retrospective cohort study , logistic regression , cancer , intensive care medicine , emergency medicine , pathology

Guideline-recommended therapy for metastatic non-small cell lung cancer (mNSCLC) encourages evidence-based treatment; however, there is a knowledge gap regarding the influence of guideline-recommended initiation of therapy on outcomes and cost.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog